PARADIGM

NCT02394795 📎

Regimen

Experimental
Panitumumab + mFOLFOX8
Control
Bevacizumab + mFOLFOX8

Population

RAS wild-type metastatic CRC, 1L, previously untreated; pre-specified primary analysis in left-sided tumors.

Key finding

1L RAS-wt mCRC (all-comer): mOS panitumumab 36.2 vs bev 31.3 mo (HR 0.84, 95% CI 0.72-0.98, p=0.03); left-sided tumors: mOS 37.9 vs 34.3 mo (HR 0.82, p=0.03, pre-specified primary); right-sided: mOS 20.8 vs 23.3 mo (HR 1.09, p=0.72) — no benefit; prospectively validated sidedness interaction

Source: PMID 37071094

Timeline

    Guideline citations

    • NCCN Colon (p.142)
    • NCCN Rectal (p.160)